Cartesian Therapeutics (RNAC) Change in Acquisitions & Divestments (2016 - 2023)

Cartesian Therapeutics (RNAC) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $28.3 million the latest figure, recorded in Q1 2023.

• In Q1 2023, Change in Acquisitions & Divestments rose 182.54% year-over-year to $28.3 million; the TTM figure through Dec 2023 stood at $28.3 million (up 43.42% YoY), while the FY2023 annual figure was $28.3 million, up 43.42% from the prior year.
• Change in Acquisitions & Divestments climbed to $28.3 million in Q1 2023 per RNAC's latest filing, from $5.7 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $28.3 million in Q1 2023 and bottomed at -$14.4 million in Q4 2019.
• Historically, Change in Acquisitions & Divestments has averaged $6.6 million across 4 years, with a median of $6.0 million in 2021.
• Annual changes were most pronounced in 2019 — Change in Acquisitions & Divestments tumbled 134.47% — and 2023, when it surged 182.54%.
• Cartesian Therapeutics' Change in Acquisitions & Divestments stood at -$14.4 million in 2019, then jumped by 169.65% to $10.0 million in 2021, then tumbled by 43.0% to $5.7 million in 2022, then jumped by 395.68% to $28.3 million in 2023.
• Business Quant data shows RNAC's Change in Acquisitions & Divestments at $28.3 million in Q1 2023, $5.7 million in Q4 2022, and $4.0 million in Q3 2022.